Cumberland Pharmaceuticals Inc. (CPIX)
NASDAQ: CPIX · IEX Real-Time Price · USD
1.760
+0.125 (7.65%)
At close: Apr 26, 2024, 4:00 PM
1.770
+0.010 (0.57%)
After-hours: Apr 26, 2024, 4:00 PM EDT
CPIX Revenue
In the year 2023, Cumberland Pharmaceuticals had annual revenue of $39.55M, a decrease of -5.85%. Revenue in the quarter ending December 31, 2023 was $9.35M with 2.51% year-over-year growth.
Revenue (ttm)
$39.55M
Revenue Growth
-5.85%
P/S Ratio
0.63
Revenue / Employee
$434,643
Employees
91
Market Cap
24.95M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 39.55M | -2.46M | -5.85% |
Dec 31, 2022 | 42.01M | 6.03M | 16.75% |
Dec 31, 2021 | 35.99M | -1.46M | -3.89% |
Dec 31, 2020 | 37.44M | 3.05M | 8.88% |
Dec 31, 2019 | 34.39M | 5.04M | 17.19% |
Dec 31, 2018 | 29.34M | -11.81M | -28.69% |
Dec 31, 2017 | 41.15M | 8.12M | 24.60% |
Dec 31, 2016 | 33.03M | -493.49K | -1.47% |
Dec 31, 2015 | 33.52M | -3.38M | -9.17% |
Dec 31, 2014 | 36.90M | 4.87M | 15.22% |
Dec 31, 2013 | 32.03M | -16.82M | -34.44% |
Dec 31, 2012 | 48.85M | -2.29M | -4.48% |
Dec 31, 2011 | 51.14M | 5.27M | 11.48% |
Dec 31, 2010 | 45.88M | 2.34M | 5.37% |
Dec 31, 2009 | 43.54M | 8.46M | 24.13% |
Dec 31, 2008 | 35.08M | 7.01M | 24.98% |
Dec 31, 2007 | 28.06M | 10.25M | 57.52% |
Dec 31, 2006 | 17.82M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cue Health | 70.94M |
Marpai | 37.16M |
Nephros | 14.24M |
Lumos Pharma | 2.05M |
TherapeuticsMD | 1.30M |
Aptorum Group | 1.20M |
Bullfrog AI | 65.00K |
Biora Therapeutics | 4.00K |
CPIX News
- 24 days ago - NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS - PRNewsWire
- 7 weeks ago - Cumberland Pharmaceuticals Reports Annual 2023 Financial Results - PRNewsWire
- 2 months ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS - PRNewsWire
- 6 months ago - Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results - PRNewsWire
- 6 months ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS - PRNewsWire
- 7 months ago - NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE - PRNewsWire
- 9 months ago - Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023 - PRNewsWire
- 9 months ago - CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS - PRNewsWire